High-Content Phenotypic Screening of Existing Drugs for the Treatment of Rett Syndrome

Christopher Gibson, PhD & Dean Li, MD, PhD | Recursion Pharmaceuticals

$50,000 AWARDED

Recursion combines experimental biology and bioinformatics in a unique drug screening platform. Recursion creates human cellular models of disease and establishes a disease profile based on identifying changes in thousands of structural (morphological) and functional (activity) parameters. These structural and functional changes are then used as the basis of a chemical suppressor screen to identify compounds with strong potential for efficacy in the disease model. For this project RNA interference will be used to genetically manipulate MECP2 in four human cell lines.  The resulting assay will be screened.

Current Projects